Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of an Implantable Microdevice to Evaluate Drug Responses in Situ in Early-stage Triple-negative Breast Cancer

NCT05774886 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT05774886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05774886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of an Implantable Microdevice to Evaluate Drug Responses in Situ in Early-stage Triple-negative Breast Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Withdrawn
Start date
May 31, 2023
Completion date
September 1, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer stage ii, breast cancer stage iii, breast carcinoma, breast neoplasms, early stage triple-negative breast carcinoma, triple negative breast cancer